ALEXANDRIA, Va., July 15 -- United States Patent no. 12,662,531, issued on June 23, was assigned to FUTUREGEN BIOPHARMACEUTICAL (BEIJING) Co. LTD. (Beijing).
"CLDN18.2 antibody and use thereof" was invented by Zhaoyu Jin (Beijing), Yun Li (Beijing), Feng Li (Beijing), Naifan Huo (Beijing), Xiumei Jin (Beijing), Li Ren (Beijing) and Zhexian Yan (Beijing).
According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a CLDN18.2-combined antibody and an unfucosylated form thereof. Further provided are a preparation method for the antibody, a conjugate, and a composition containing the antibody, and use thereof in the treatment of a disease such as cancer."
The patent was filed on July 10, 2020, under Application N...